Research

Showing 385–400 of 514 results

• 

  Synthetic irreversible inhibitors

  Pepbloc AEBSF

• 

  Synthetic reversible inhibitors

  PEPBLOC FG

• 

  Synthetic reversible inhibitors

  Pepbloc NAPAP

• 

  Phospholipids

  Phospholipids 0.25 mM

• 

  Phospholipids

  Phospholipid-TGT Emulsion 0,5 mM

• 

  Congenital deficient plasmas (Kits)

  Deficient Human Plasma in Native VWF (VWD Type 1)

• 

  Congenital deficient plasmas (Kits)

  Deficient Human Plasma in Native VWF (VWD Type 2A)

• 

  Congenital deficient plasmas (Kits)

  Deficient Human Plasma in Native VWF (VWD Type 2B)

• 

  Congenital deficient plasmas (Kits)

  Deficient Human Plasma in Native VWF (VWD Type 3)

• 

  Genetic disorders

  Plasma from heterozygous prothrombin gene mutation G20210A

• 

  Plasmas with anticoagulant drugs

  Plasma with direct thrombin inhibitor (Lepirudin)

• 

  Genetic disorders

  Plasma with Factor V Leiden (heterozygous mutation)

• 

  Genetic disorders

  Plasma with Factor V Leiden (homozygous mutation)

• 

  High Factor plasmas

  Plasma with high level of C protein: > 150 %

• 

  Fibrinogen plasmas

  Plasma with high level of fibrinogen: 6 – 10 g/L

• 

  High Factor plasmas

  Plasma with high level of S protein: > 150 %